All In Biotech

Investigational drug · Phase 2

ACT-777991

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Segmental Vitiligo.

Phase 2

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "ACT-777991"

First trial start

2026

Oct 6, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ACT-777991", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-Segmental Vitiligo

Approved drugs for the same conditions: Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "ACT-777991" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Non-Segmental Vitiligo

  • VC005Phase 35 trials

    Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis

  • SHR0302Phase 32 trials

    Jiangsu HengRui Medicine Co., Ltd. · Non-segmental Vitiligo, Psoriatic Arthritis

  • GIA632Phase 23 trials

    Novartis · Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus

  • SHR0302BasePhase 22 trials

    Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo

  • EI-001Phase 21 trial

    Elixiron Immunotherapeutics (Hong Kong) Ltd. · Non-segmental Vitiligo

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.